# AIA-PACK® Series Prostate Health



# **Screening with Meaning**

In the US, prostate cancer is the most common cancer in men and the second leading cause of cancer death. It is estimated that 1 in 8 men may be slow and asymptomatic, screening and early detection is key to reducing mortality rates.<sup>1</sup>

The Prostate Specific Antigen (PSA) test is the first FDA-approved blood test for screening of prostate cancer when combined with a digital rectal examination. It is also used for disease management through surveillance, assessment of response to therapy and monitoring of recurrence in follow up patients. This has led to the reduction of prostate cancer deaths in the US and Europe.<sup>2</sup>

Using the right assay is important for gathering meaningful results for early diagnosis and monitoring with confidence. Tosoh's PSA assay is based on the classical Hybritech<sup>®</sup> equimolar assay that measures PSA with better diagnostic accuracy compared to nonequimolar PSA tests. Our offering delivers the quality, precision and accuracy that you can rely on.



TOSOH BIOSCIENCE

### **Universal Reagent**

Tosoh's AIA-PACK test cup format works with every Tosoh automated immunoassay system allowing for a seamless transition from one system to the other, ensuring consistent results in an efficient and economical process.

### **Save Time** and Money

Tosoh's AIA-PACK test cups are single, unitized cups that use a dry reagent format that ensures calibration stability of up to 90 days.

### No Contamination, More Traceability

Because there is no transfer of reagents the risk of contamination is eliminated. The unique bichromatic fluorescence kinetic measurement ensures a high analytical and functional sensitivity for all assays. AIA-PACK test cups and trays are labelled with the assay code and lot number for automated scheduling and inventory.

- Based on classical Hybritech equimolar monoclonal antibodies,<sup>3</sup> the first FDA-approved assay for prostate cancer detection and monitoring and the gold standard upon which the FDA-approved clinical cut-off is based.
- Equimolar PSA assay that shows better diagnostic sensitivity and specificity compared to nonequimolar PSA assays.<sup>4,5</sup>
- Trustworthy and quality results by providing an accurate PSA test results.4
- Save on costs by only using what you need with Tosoh's unit-dose test cup.

# **Tosoh's Equimolar PSA Test** aPA 67

# Choose Wisely. Choose Tosoh.



Accurate & precise



Extensive test menu



Specific & sensitive



Up to 90 day calibration stability



Correlation with gold standard methods



10 min incubation times



**Biotin-free** immunoassays



Automated workflows

# Available for Labs and Workloads of All Sizes



AIA<sup>®</sup>-360



**AIA-900** Benchtop



AIA-900 with 9 Tray Sorter Also available with 19 tray sorter option and as Loader model



AIA-2000

Tosoh products are for Prescription use only as In-Vitro Diagnostics.



## Tosoh Bioscience, Inc.

3600 Gantz Road Grove City, OH 43123 Tel: (800) 248-6764 Fax: (650) 615-0415 www.tosohbioscience.us

#### References

- 1. David Crosby, Sangeeta Bhatia. Early detection of cancer. Epub 2022 Mar 18
- 2. Schröder, M.D. et al; Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009:360:1320-8.
- 3. Prestigiacomo, et al. A Comparison of 4 Ultrasensitive Prostate Specific Antigen Assays for Early Detection of Residual Cancer after Radical Prostatectomy. The Journal of Urology 1994; 152: 1515-1519.
- 4 Jean-Sébastien R Thomas R THE CLINICAL IMPACT OF WHO STANDARDIZATION OF PSA ASSAYS JMB 27: 161-168, 2008
- 5. Andrew W Roddam, Janet Rimmer. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem2006.